A detailed history of C World Wide Group Holding A transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, C World Wide Group Holding A holds 140,329 shares of SRPT stock, worth $16 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares
140,329
Previous 140,329 -0.0%
Holding current value
$16 Million
Previous $22.2 Million 20.95%
% of portfolio
0.18%
Previous 0.24%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 02, 2023

BUY
$117.53 - $155.99 $2.35 Million - $3.12 Million
20,000 Added 16.62%
140,329 $19.3 Million
Q4 2020

Feb 05, 2021

SELL
$125.56 - $178.74 $3.14 Million - $4.47 Million
-25,000 Reduced 17.2%
120,329 $20.5 Million
Q3 2019

Nov 04, 2019

BUY
$72.81 - $156.91 $2.18 Million - $4.71 Million
30,000 Added 26.01%
145,329 $10.9 Million
Q2 2019

Aug 02, 2019

BUY
$112.21 - $151.95 $10.1 Million - $13.7 Million
90,000 Added 355.32%
115,329 $17.5 Million
Q1 2019

May 03, 2019

SELL
$106.67 - $151.68 $1.03 Million - $1.46 Million
-9,639 Reduced 27.57%
25,329 $3.02 Million
Q4 2018

Feb 12, 2019

SELL
$97.32 - $148.76 $1.18 Million - $1.8 Million
-12,078 Reduced 25.67%
34,968 $3.82 Million
Q3 2018

Nov 05, 2018

SELL
$115.31 - $161.51 $2.58 Million - $3.61 Million
-22,381 Reduced 32.24%
47,046 $7.6 Million
Q2 2018

Aug 03, 2018

BUY
$71.74 - $153.69 $154,599 - $331,201
2,155 Added 3.2%
69,427 $9.18 Million
Q1 2018

May 03, 2018

SELL
$54.02 - $82.27 $1.79 Million - $2.73 Million
-33,206 Reduced 33.05%
67,272 $4.98 Million
Q4 2017

Feb 07, 2018

SELL
$47.64 - $56.75 $1.05 Million - $1.25 Million
-21,991 Reduced 17.96%
100,478 $5.59 Million
Q3 2017

Nov 06, 2017

BUY
$35.73 - $47.15 $4.38 Million - $5.77 Million
122,469
122,469 $5.56 Million

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track C World Wide Group Holding A Portfolio

Follow C World Wide Group Holding A and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of C World Wide Group Holding A, based on Form 13F filings with the SEC.

News

Stay updated on C World Wide Group Holding A with notifications on news.